Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Epilepsy × enzalutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 93 Breast Neoplasms 10 Neoplasm Metastasis 7 Prostatic Neoplasms, Castration-Resistant 6 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 3 Castration-resistant Prostate Cancer 3 Urinary Bladder Neoplasms 2 Prostate Cancer Metastatic 2 Prostate Adenocarcinoma 2 Ovarian Neoplasms 2 Neoplasms 2 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2 Metastatic Castration-Resistant Prostate Cancer 2 Metastatic Castration Resistant Prostate Cancer 2 Castration Resistant Metastatic Prostate Cancer 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Urinary Bladder Diseases 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Ureteral Diseases 1 Thrombocytosis 1 Stomach Neoplasms 1 Solid Tumor 1 Salivary Cancer 1 Recurrent Endometrial Endometrioid Adenocarcinoma 1 Prostatic Diseases 1 Prostate Carcinoma Metastatic to the Bone 1 Primary Myelofibrosis 1

Interventions

Sirolimus 4 Everolimus 3 Anticonvulsants 2 ziprasidone 1 perampanel 1 enzalutamide 1 clevidipine 1 brivaracetam 1 Zolpidem 1 Warfarin 1 Vigabatrin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Tobramycin 1 Therapeutic Touch 1 Temozolomide 1 Surgical Procedures, Operative 1 Sulfasalazine 1 Spironolactone 1 Sevoflurane 1 Sevelamer 1 Saline Solution 1 Rocuronium 1 Registries 1 Radiotherapy 1 Propofol 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04290611 2023-04-13

VENDY

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Brain Diseases, Epilepsy, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡